MRKMerck Sharp & Dohme LLCRunning, no new patients
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 96 (planned)
- Started
- May 13, 2025
- Main results expected
- Mar 12, 2032
- Fully finished
- Mar 12, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to approximately 81 months
Percentage of Participants with at Least One Adverse Event (AE)
Measured over: Up to approximately 81 months
Percentage of Participants Who Discontinued Medication Due to an AE
Measured over: Up to approximately 24 months
Changes Tremor has spotted
Status changed: Signing up patients → Running, no new patients. Usually normal progress.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · status_changed · overall_status
old: "RECRUITING"
new: "ACTIVE_NOT_RECRUITING"
Trial ID NCT06780085 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC